sun pharma shares: Sun Pharma Q3 Results Preview: Net profit may fall 7%; sales seen rising 8-9%

The drugmaker had reported a profit of Rs 1,852 crore in the year-ago quarter.

Net sales for the pharma major is seen rising 9.04 per cent YoY to Rs 9,635 crore from Rs 8,836 crore in the same quarter last year. Ebitda could climb to Rs 2,486 crore from Rs 2,406 crore in the year-ago quarter, the poll suggested.

Ebitda margin is seen shrinking to 25.9 per cent from 27.2 per cent YoY. US specialty sales are seen rising $10 million sequentially to $157 million.

Edelweiss Securities sees profit falling 7.7 per cent YoY to Rs 1,709.8 crore. Sales is seen rising 8.3 per cent YoY to Rs 9,571 crore.

According to the brokerage, the US revenue may rise 2 per cent sequentially to $370 million in cc on account of Winlevi launch and a good ramp-up in Ilumya (up 65 per cent) and Cequa (up 8 per cent) growth for October and November, offset partly by a decline in Absorica post genericisation and base business price erosion.

“Taro US revenues are expected to remain flat sequentially to $100 million. We expect domestic formulations to report growth of 14 per cent YoY benefiting from a recovery in chronic therapies and seasonality. We expect overall Ebitda margins at 26.2 per cent, declining 200 bps QoQ as a result of increased input cost pressures, R&D ramp up and Winlevi cost,” Edelweiss said.

ICICIdirect expects revenues to grow 9.3 per cent YoY to Rs 9,656.9 crore, mainly due to 12 per cent YoY growth in domestic formulations to Rs 3,083.1 crore.

Taro’s sales are expected to grow 6.8 per cent YoY to Rs 1,103.6 crores while the US (ex-Taro) is likely to grow 4.2 per cent YoY to Rs 1,799.9 crore. Ebitda margins are expected to decline 73 bps to 26.5 per cent while Ebitda is expected to grow 6.4 per cent YoY to Rs 2,559.1 crore, the brokerage said.

This brokerage is expecting adjusted PAT to decline 5.6 per cent YoY to Rs 1,749 crore.